logo
WA Public Trustee office charges woman with dementia $137,000 to manage assets at a loss

WA Public Trustee office charges woman with dementia $137,000 to manage assets at a loss

An "overworked and under-resourced" state agency has charged a woman with dementia a six-figure bill while managing her assets at a loss.
Public trustees control the finances of some of the community's most vulnerable people who have been deemed incapable of making their own decisions, for example if a person has a cognitive impairment from a head injury.
It's illegal to identify people across most of Australia who are, or were, under state administration or guardianship.
Daniel, not his real name, said he regrets ignoring warnings from lawyers to avoid the WA Public Trustee's office.
"We enquired to a barrister ... she recommended not to go through public trustees," Daniel told the ABC.
Daniel's mother had dementia, and was put into state administration under the Public Trustee during a family dispute.
Over eight years, the state charged her $137,000 in fees for managing her finances and assets, including three properties in Perth.
"For one of the properties, I managed, and they still charged us for it ... I can't see how they can be justified in charging for something they never even did," Daniel said.
Financial statements, seen by the ABC, show the Public Trustee spent about $24,000 of Daniel's mother's money to repair one of the properties and replace an oven.
The trustee's office then ran two of the houses as rental properties at a loss for several years.
The most profitable year was straight after the renovations — the repaired three-bedroom house in Perth took in $17,114 in rent over a year which averages out to $329 per week.
The average rent in the area that year was $461 per week according to the local council.
Two years later, the same property brought in an annual total of $6,619 in rent, which fell thousands of dollars short of covering bills, and property and land taxes.
"It's disgusting how a property in [Perth] can lose so much money," Daniel said.
"They [mum and dad] worked their whole lives for all this — and it wasn't only their lives, we as a family worked together to build up these assets — and they [the Public Trustee's office] ran them at a loss."
Do you know more about this story? Contact Cason Ho
Do you know more about this story? Contact Cason Ho
Several organisations which help people under state administration in WA have told the ABC they can't speak publicly about concerns they have with the system, out of fear of jeopardising their relationship with the Public Trustee and putting future cases at risk.
The organisations include community legal centres and advocacy organisations which receive government funding.
Public trustees are mostly self-funded by charging some clients more to subsidise others that can't afford to pay — in Western Australia and Queensland, the trustees are completely self-funded.
The state is assigned as an administrator of "last resort" to manage a person's money and assets in their best interest, for a fee.
The WA Public Trustee manages $1.7 billion worth of assets, as of its latest annual report.
In response to written questions to the WA Public Trustee, a Department of Justice spokesperson said the agency was bound by confidentiality provisions, and did not directly answer questions about Daniel's mother's case, or concerns over organisations' fears of speaking publicly.
"The Public Trustee charges fees in accordance with its Scale of Fees which is reviewed annually ... subject to scrutiny by the Joint Standing Committee on Delegated Legislation," the statement read.
"Any person dissatisfied with the way in which the Public Trustee has dealt with their complaint has several avenues for investigating their concerns, including lodging a complaint with the Ombudsman or the State Administrative Tribunal."
Succession lawyer Morgan Solomon works in the same field of law which falls under part of public trustees' remits, and says it's "no secret" the government agencies are stretched thin.
"Dealing with the affairs of someone after they've passed away is inherently complicated work — it's the unravelling of essentially a life's worth of materials," he said.
"The amount of work that ... staff there have to do is extraordinary, their caseload I think is in many cases unmanageable ... they do what they can with what they have."
Mr Solomon urged the public to consider having wills prepared, and also enduring powers of attorney and guardianship.
"A will comes into being only when you pass away, but there are other catastrophes that can befall us, which is the loss of mental capacity which can affect anyone," he said.
"We just did a survey of a thousand Western Australians ... 60 per cent of families in WA are anticipating some kind of inheritance dispute, which floored us."
Daniel said he believed there was a need for the state to manage the finances of some vulnerable people as a last resort, but said there should be more transparency.
"They don't look after the people that really need it," Daniel said.
There have been numerous accounts of state trustees and guardians around the country providing questionable care, and allegations of exorbitant fees for little work.
In 2023, the WA Government committed to implementing an independent governing board to improve oversight of the Public Trustee, and the development of a more "transparent and equitable" fee model.
The WA Law Reform Comission is also reviewing the state's guardianship and administration legislation.
A WA parliamentary committee will be questioning the Public Trustee this week.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Strategic CEO hire to drive NeuroScientific stem cell therapy release
Strategic CEO hire to drive NeuroScientific stem cell therapy release

The Age

time10 minutes ago

  • The Age

Strategic CEO hire to drive NeuroScientific stem cell therapy release

NeuroScientific Biopharmaceuticals has made a second heavy-hitting appointment in less than a week, bringing in experienced Melbourne-based executive Nathan Smith as its chief executive officer, as the company gears up for the commercial release of its innovative StemSmart stem cell technology. Smith has extensive experience in cell and gene therapies in senior commercial, operational and strategic roles in Australia and the United States, which should prove invaluable as the company navigates the regulatory and commercial pathways for its innovative StemSmart technology. The company says his deep expertise in good practice manufacturing will be critical for converting the biotechnology startup into a scaled-up commercial stem cell company. NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopgen. StemSmart uses a specific type of stem cell, mesenchymal stromal stem cells (MSC), as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'I was attracted to NSB given the historical success of StemSmart in multiple serious clinical disorders and the clear potential of the technology for further development.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith Adding to the company's ranks of highly credentialled personnel, NeuroScientific announced on Friday that it had also recruited well-regarded Perth-based paediatric haematologist and oncologist Dr Catherine Cole as its chief medical officer. The news of both appointments has continued to fuel a stellar rise in the company's share price, which traded 11.3 per cent higher today to 24.5 cents on the best turnover since April. The company's share price is up 360 per cent since the start of June. Smith was the director of business development at Melbourne's Cell Therapies, which develops and manufactures advanced cell-based therapies and is located within the city's pioneering Peter MacCallum Cancer Centre. He has held key roles at Genzyme Corporation, Mesoblast Inc and GlaxoSmithKline in the US, as well as other leading companies in the cell therapy sector.

Strategic CEO hire to drives NeuroScientific stem cell therapy release
Strategic CEO hire to drives NeuroScientific stem cell therapy release

West Australian

time10 minutes ago

  • West Australian

Strategic CEO hire to drives NeuroScientific stem cell therapy release

NeuroScientific Biopharmaceuticals has made a second heavy-hitting appointment in less than a week, bringing in experienced Melbourne-based executive Nathan Smith as its chief executive officer, as the company gears up for the commercial release of its innovative StemSmart stem cell technology. Smith has extensive experience in cell and gene therapies in senior commercial, operational and strategic roles in Australia and the United States, which should prove invaluable as the company navigates the regulatory and commercial pathways for its innovative StemSmart technology. The company says his deep expertise in good practice manufacturing will be critical for converting the biotechnology startup into a scaled-up commercial stem cell company. NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopgen. StemSmart uses a specific type of stem cell, mesenchymal stromal stem cells (MSC), as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. Adding to the company's ranks of highly credentialled personnel, NeuroScientific announced on Friday that it had also recruited well-regarded Perth-based paediatric haematologist and oncologist Dr Catherine Cole as its chief medical officer. The news of both appointments has continued to fuel a stellar rise in the company's share price, which traded 11.3 per cent higher today to 24.5 cents on the best turnover since April. The company's share price is up 360 per cent since the start of June. Smith was the director of business development at Melbourne's Cell Therapies, which develops and manufactures advanced cell-based therapies and is located within the city's pioneering Peter MacCallum Cancer Centre. He has held key roles at Genzyme Corporation, Mesoblast Inc and GlaxoSmithKline in the US, as well as other leading companies in the cell therapy sector. NeuroScientific says that having led programs across their full therapeutic cycle, including pre-clinical development and clinical trials, Smith has extensive experience in navigating regulatory approvals and developing commercial product supplies. Smith said he was excited to help advance the technology and make it accessible to patients with serious and life-threatening conditions. 'I was attracted to NSB given the historical success of StemSmart in multiple serious clinical disorders and the clear potential of the technology for further development,' he said. The high-level executive duo of Smith and Cole join a strong leadership team, which also includes Perth-based haematology medical scientist Dr Marian Sturm, as NeuroScientific's chief scientific officer. Sturm pioneered the use of the MSC used in StemSmart over the past 20 years in her former role as facility director of Royal Perth Hospital's Cell and Tissue Therapies centre. StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special media, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes. The cells have been used many times over the years via early-phase clinical trials, studies and on compassionate grounds, with promising results. Later in the year, the company expects to receive the interim results from its latest compassionate trial involving patients with difficult-to-treat fistulising Crohn's disease, in which an open wound develops from a gut flare-up that extends out to the skin. A successful trial will help the company validate its proprietary StemSmart technology in this patient group, who otherwise have limited treatment options. NeuroScientific has created a bit of a whirlwind this year with its Isopogen acquisition, re-energised leadership team and a $3.5 million capital raise. The funding has handed the company a $7.5 million war chest to support further trials and development and helped it generate plenty of momentum towards its long-term goal of partial or full registration for StemSmart, first up as a Crohn's treatment. Is your ASX-listed company doing something interesting? Contact:

WA government broadens scope of e-rideable inquiry following woman's death in dirt bike incident
WA government broadens scope of e-rideable inquiry following woman's death in dirt bike incident

ABC News

time10 minutes ago

  • ABC News

WA government broadens scope of e-rideable inquiry following woman's death in dirt bike incident

The WA government will expand an inquiry into the safety of e-rideables to include electric dirt bikes, following the death of a 59-year-old woman in Perth. She died in Picnic Cove Park in Edgewater after a crash involving a high-powered electric motorcycle on Saturday. A 17-year-old boy has since appeared in court charged with manslaughter, driving without a license and using an unlicensed vehicle on a road in relation to the woman's death. It comes as a state parliamentary committee probes the safety, regulation and penalties associated with electric powered personal mobility devices, known as e-rideables. In Western Australia, an e-rideable is defined as something that weighs 25 kilograms or less and has a speed limit of 25 kph on level ground. The bike involved in the crash would not be considered an e-rideable under that definition. But Road Safety Minister Reece Whitby said he would be asking the committee to expand its scope. The review is also looking at the usage and policing of e-rideables in entertainment precincts and other highly used pedestrian areas. Ahead of any recommendations by the inquiry, the minister said he had his own ideas around how to limit the use of e-rideables in built-up areas. "For instance the circumstances where they can be used on footpaths, the speed, I think there's new technology that can automatically limit an e-scooter on a footpath," he said. The pedestrian's death in Edgewater was not the first involving a battery-powered vehicle this year. In June, 51-year-old Thanh Phan was the first pedestrian to die after being hit by an e-scooter in WA. In a plea to prevent further serious incidents, Mr Phan's family called for a review of the governance and safety regulations regarding hired e-scooters. The City of Perth subsequently suspended the hiring of e-scooters, in response to the tragedy. Royal Perth Hospital's head of trauma services Dieter Weber told the ABC his team saw serious injuries from e-scooter incidents "daily". WA Opposition Leader Basil Zempilas said including e-bikes into the parliamentary inquiry was crucial. "There are too many fatalities and now too many incidents with these forms of transportation," he said. Mr Zempilas said safety had to be "the top priority". "We understand accessibility and transportation methods that aid people getting around is really useful, but not at the expense of people's safety," he said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store